Robert W. Baird Forecasts Strong Price Appreciation for LivaNova (NASDAQ:LIVN) Stock

LivaNova (NASDAQ:LIVN) had its price target raised by Robert W. Baird from $66.00 to $72.00 in a research report report published on Thursday, Benzinga reports. The firm currently has an outperform rating on the stock.

Several other analysts have also issued reports on the company. The Goldman Sachs Group assumed coverage on LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 target price on the stock. Needham & Company LLC boosted their price objective on LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, Stifel Nicolaus boosted their target price on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, July 25th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, LivaNova has an average rating of “Buy” and an average price target of $69.17.

LivaNova Stock Down 1.4 %

NASDAQ:LIVN traded down $0.74 on Thursday, hitting $50.88. The stock had a trading volume of 136,367 shares, compared to its average volume of 620,196. LivaNova has a 1 year low of $42.75 and a 1 year high of $64.47. The firm’s fifty day simple moving average is $51.04 and its two-hundred day simple moving average is $53.14. The stock has a market cap of $2.76 billion, a P/E ratio of 122.90 and a beta of 1.00. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.94 and a current ratio of 3.37.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.15. The company had revenue of $318.60 million during the quarter, compared to analyst estimates of $305.05 million. LivaNova had a net margin of 1.91% and a return on equity of 13.81%. Analysts predict that LivaNova will post 2.58 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Arizona State Retirement System increased its holdings in LivaNova by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock worth $828,000 after acquiring an additional 299 shares in the last quarter. State of Michigan Retirement System increased its stake in shares of LivaNova by 2.3% in the first quarter. State of Michigan Retirement System now owns 13,211 shares of the company’s stock worth $739,000 after purchasing an additional 300 shares in the last quarter. Fifth Third Bancorp raised its position in shares of LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after purchasing an additional 332 shares during the period. Hexagon Capital Partners LLC lifted its stake in shares of LivaNova by 117.8% during the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after buying an additional 370 shares in the last quarter. Finally, State of Alaska Department of Revenue boosted its holdings in LivaNova by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after buying an additional 425 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.